Research Analysts Set Expectations for CRVS Q3 Earnings

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) – Investment analysts at HC Wainwright boosted their Q3 2025 earnings per share (EPS) estimates for Corvus Pharmaceuticals in a note issued to investors on Monday, August 11th. HC Wainwright analyst S. Lee now forecasts that the company will earn ($0.14) per share for the quarter, up from their previous forecast of ($0.15). The consensus estimate for Corvus Pharmaceuticals’ current full-year earnings is ($0.63) per share. HC Wainwright also issued estimates for Corvus Pharmaceuticals’ Q4 2025 earnings at ($0.14) EPS, FY2025 earnings at ($0.51) EPS, Q1 2026 earnings at ($0.12) EPS, Q2 2026 earnings at ($0.12) EPS, Q4 2026 earnings at ($0.13) EPS, FY2026 earnings at ($0.50) EPS and FY2027 earnings at ($0.40) EPS.

Corvus Pharmaceuticals (NASDAQ:CRVS) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.10) EPS for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.03.

CRVS has been the subject of a number of other reports. Mizuho set a $11.00 target price on Corvus Pharmaceuticals and gave the stock an “outperform” rating in a research report on Tuesday, May 20th. Wall Street Zen raised Corvus Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, August 9th. Finally, Oppenheimer reissued an “outperform” rating and issued a $17.00 target price (up from $15.00) on shares of Corvus Pharmaceuticals in a research report on Friday, May 9th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $15.00.

Corvus Pharmaceuticals Trading Down 3.0%

Shares of CRVS opened at $4.85 on Thursday. The company has a market capitalization of $361.37 million, a price-to-earnings ratio of -4.80 and a beta of 0.42. The stock has a 50 day moving average of $4.23 and a 200 day moving average of $4.04. Corvus Pharmaceuticals has a 12 month low of $2.54 and a 12 month high of $10.00.

Insider Transactions at Corvus Pharmaceuticals

In other news, Director Peter A. Thompson sold 1,176,332 shares of the firm’s stock in a transaction on Friday, June 27th. The stock was sold at an average price of $4.16, for a total value of $4,893,541.12. Following the completion of the transaction, the director directly owned 7,165,006 shares of the company’s stock, valued at $29,806,424.96. This trade represents a 14.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 28.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Corvus Pharmaceuticals

A number of large investors have recently made changes to their positions in CRVS. Geode Capital Management LLC boosted its holdings in shares of Corvus Pharmaceuticals by 0.7% in the fourth quarter. Geode Capital Management LLC now owns 566,863 shares of the company’s stock worth $3,034,000 after acquiring an additional 3,854 shares during the period. Renaissance Technologies LLC boosted its holdings in shares of Corvus Pharmaceuticals by 1.1% in the fourth quarter. Renaissance Technologies LLC now owns 390,688 shares of the company’s stock worth $2,090,000 after acquiring an additional 4,100 shares during the period. Raymond James Financial Inc. bought a new position in shares of Corvus Pharmaceuticals in the fourth quarter worth $583,000. Barclays PLC boosted its holdings in shares of Corvus Pharmaceuticals by 10,601,800.0% in the fourth quarter. Barclays PLC now owns 106,019 shares of the company’s stock worth $567,000 after acquiring an additional 106,018 shares during the period. Finally, XTX Topco Ltd boosted its holdings in shares of Corvus Pharmaceuticals by 306.2% in the fourth quarter. XTX Topco Ltd now owns 57,213 shares of the company’s stock worth $306,000 after acquiring an additional 43,127 shares during the period. 46.64% of the stock is owned by institutional investors.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.